Globalization, Development as a Regenerative Medicine Products Company and Significant Growth Under Takara Bio Medium-Term Management Plan 2019
First written in FY2018-Q1. 8 of 15 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
中期経営計画2019に代わる中期経営計画2025のもと、試薬・機器事業とCDMO事業を通じた創薬基盤技術開発およびグローバルプラットフォーマー化を継続している。 - FY2024-Q3RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
Under Long-Term Management Vision 2025 and Medium-Term Management Plan 2025, the Group continued its policy of becoming a global platform company through the Reagents and Instruments Business and CDMO Business. - FY2024-Q2RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
長期経営構想2025および中期経営計画2025のもと、創薬基盤技術開発とグローバルプラットフォーマー化を進める方針を継続している。 - FY2024-Q1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2025, ending in fiscal 2025, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and CDMO business, with the aim of becoming a global platform company supporting the infrastructure of the life sciences industry.」
長期経営構想2025の後半3カ年を対象とする中期経営計画2025のもと、グローバルプラットフォーマーを目指す方針を継続している。 - FY2023ReframedAnnual report
「The Group formulated Long-Term Management Concept 2025 in 2020 and has been implementing it. In May 2023, it also formulated Medium-Term Management Plan 2025, a specific three-year execution plan for the latter half of Long-Term Management Concept 2025.」
中期経営計画2019から、長期経営構想2025の後半3カ年を対象とする中期経営計画2025へ実行計画を更新した。 - FY2021-Q1ReframedAnnual report
「Under the newly formulated Long-Term Management Vision 2025 and Medium-Term Management Plan 2022, the Group pursued initiatives aimed at becoming a drug discovery company by advancing the development of foundational technologies for biopharmaceutical drug discovery and continuously creating new modalities through its research reagents and scientific instruments business and CDMO business.」
中期経営計画2019を軸としたグローバル企業化・再生医療等製品企業化の表現から、長期経営構想2025と中期経営計画2022のもとで創薬企業を目指す枠組みへ移行した。 - FY2020-Q3RestatedAnnual report
「Against this backdrop, the Group continued initiatives aimed at enhancing its presence as both a global company and a regenerative medicine products company and achieving substantial growth, as set out in the overall policy of Takara Bio Medium-Term Management Plan 2019, the final year of which began in the fiscal year ended March 2018.」
中期経営計画2019の最終年度において、グローバル企業化・再生医療等製品企業化と飛躍的成長の方針を継続している。 - FY2020-Q2RestatedAnnual report
「Against this backdrop, the Group continued initiatives aimed at enhancing its presence as both a global company and a regenerative medicine products company and achieving substantial growth, as set out in the overall policy of Takara Bio Medium-Term Management Plan 2019, the final year of which began in the fiscal year ended March 2018.」
中期経営計画2019の最終年度において、グローバル企業化・再生医療等製品企業化と飛躍的成長の方針を継続している。 - FY2019RaisedAnnual report
「本中計最終年度を迎え、修正営業利益目標6,000百万円(2018年５月11日公表)を上回る6,200百万円(2019年５月14日公表)を目指して、以下の課題に取り組み、持続的成長を実現してまいります。」
中期経営計画最終年度の営業利益目標を6,000百万円から6,200百万円へ引き上げた。 - FY2019-Q3ReframedAnnual report
「上述のとおり、グループ全体の飛躍的成長のために、健康食品およびキノコにかかる事業をそれぞれシオノギヘルスケア株式会社および株式会社雪国まいたけへ譲渡することで、より一層の経営資源の集中と選択を行うことといたしました。これにより、本中計における事業ポートフォリオに一部変更が生じることになりますが、当社グループ全体の最終年度営業利益目標6,000百万円に変更はありません。」
健康食品事業の分離完了とキノコ事業の譲渡契約により、中期経営計画の事業ポートフォリオをさらに組み替えた。一方、最終年度営業利益目標6,000百万円は維持している。 - FY2019-Q2ReframedAnnual report
「これにより、本中計における事業ポートフォリオに一部変更が生じることになりますが、当社グループ全体の最終年度営業利益目標6,000百万円に変更はありません。」
健康食品事業の会社分割により中期経営計画の事業ポートフォリオは一部変更となる一方、最終年度営業利益目標6,000百万円は維持している。 - FY2019-Q1RaisedAnnual report
「上方修正した最終年度営業利益目標6,000百万円を実現するための取り組みを推進いたしました。」
中期経営計画2019の最終年度営業利益目標を上方修正し、6,000百万円の目標を掲げている。 - FY2018-Q3RestatedAnnual report
「Against this backdrop, under the newly formulated three-year medium-term management plan, Takara Bio Medium-Term Management Plan 2019, the Group advanced the strategies for its three business divisions—biotechnology industry support, gene medicine, and medical food biotechnology—and strengthened the management base supporting them. It worked to enhance its presence as both a global company and a company specializing in regenerative medicine products, and pursued initiatives aimed at achieving significant growth.」
中期経営計画2019に基づく三事業の戦略推進、経営基盤強化、グローバル化および再生医療等製品企業化の方針を継続している。 - FY2018-Q2RestatedAnnual report
「Against this backdrop, under the newly formulated three-year medium-term management plan, Takara Bio Medium-Term Management Plan 2019, the Group advanced the strategies for its three business divisions—biotechnology industry support, gene medicine, and medical food biotechnology—and strengthened the management base supporting them. It worked to enhance its presence as both a global company and a company specializing in regenerative medicine products, and pursued initiatives aimed at achieving significant growth.」
中期経営計画2019に基づく三事業の戦略推進、経営基盤強化、グローバル化および再生医療等製品企業化の方針を継続している。 - FY2018-Q1First statedAnnual report
「Under the newly formulated three-year medium-term management plan, Takara Bio Medium-Term Management Plan 2019, the Group advanced the strategies for its three business divisions—biotechnology industry support, gene medicine, and medical food biotechnology—and strengthened the management base supporting them. It worked to enhance its presence as both a global company and a company specializing in regenerative medicine products, and pursued initiatives aimed at achieving significant growth.」
Formulated a new three-year medium-term management plan focused on advancing the three business strategies, strengthening the management base, enhancing its presence as a global company and a regenerative medicine products company, and achieving significant growth.